This webinar will provide attendees with the knowledge and skills needed to develop and produce an OTC drug product for marketing and sale in the U.S.
The Food and Drug Administration and the Consumer Product Safety Commission have regulations pertaining to OTC drugs. The U.S. Food and Drug Administration's (FDA) is responsible for the regulation and oversight of the U.S. OTC drug market. Congress has granted FDA regulatory authority over the formulation, manufacturing, labeling, marketing and promotion; and import / export of OTC drug products into the U.S. Under this current regulatory regime, there are 4 pathways that a company may follow to enter the OTC drug market including (a) following an appropriate Drug Monograph; (b) with an Agency approved New Drug Application (NDA); (c) via the currently popular Rx-to-OTC Switch Process or (d) via an ANDA citing a previously-approved product.
WHY SHOULD YOU ATTEND?
This webinar will discuss U.S. FDA and Consumer Product Safety Commission regulation of OTC drug products and strategic recommendations for mitigating the risk of enforcement action in the future. Attendees will gain an understanding of various available options for producing and selling an OTC drug product. FDA and CPSC requirements for OTC drugs will be covered. There will also be some discussion of the market differences between Rx and OTC products.
AREA COVERED
- Claims for drugs, devices, medical foods and cosmetics
- NDA, ANDA and OTC Monographs for OTC Drugs
- Rx to OTC Switches
- cGMPs for OTC drugs
- Tamper Evidence and Poison Control
- Branded Innovator, Branded Generic and Generics
LEARNING OBJECTIVES
- Gain a comprehensive understanding of how OTC drug products are regulated in the U.S
- Learn to distinguish between a potential Rx pharmaceutical product and an OTC drug
- Recognize the difference between the various pathways for commercializing an OTC drug product
- Understand how to identify and successfully navigate an OTC Drug Monograph
- Recognize when reliance on a Proposed Rule, Final Rule and/or Drug Monograph is appropriate
- Understand how to determine whether an Ingredient is considered Safe or GRAS/E for use in an OTC drug and understand the difference between Category I, II and II Ingredient designations
- Identify the required elements of a compliant OTC Drug Label
- Take away strategies for marketing and promoting OTC drug products, and for mitigating potential enforcement risks
- Possess a working knowledge of the Rx-to-OTC Switch Process
- Review and evaluate several of FDA's current OTC Monographs
WHO WILL BENEFIT?
- Regulatory affairs managers, directors and associates
- Compliance specialists
- Marketing managers
- Quality professionals
- Document control specialists
- Record retention specialists
- Senior Managers / Business Owners
- Product Managers
- Labeling and Artwork Designers
- Regulatory and Quality Professionals
- Sales and Marketing Managers
- R&D Managers and Staff
This webinar will discuss U.S. FDA and Consumer Product Safety Commission regulation of OTC drug products and strategic recommendations for mitigating the risk of enforcement action in the future. Attendees will gain an understanding of various available options for producing and selling an OTC drug product. FDA and CPSC requirements for OTC drugs will be covered. There will also be some discussion of the market differences between Rx and OTC products.
- Claims for drugs, devices, medical foods and cosmetics
- NDA, ANDA and OTC Monographs for OTC Drugs
- Rx to OTC Switches
- cGMPs for OTC drugs
- Tamper Evidence and Poison Control
- Branded Innovator, Branded Generic and Generics
- Gain a comprehensive understanding of how OTC drug products are regulated in the U.S
- Learn to distinguish between a potential Rx pharmaceutical product and an OTC drug
- Recognize the difference between the various pathways for commercializing an OTC drug product
- Understand how to identify and successfully navigate an OTC Drug Monograph
- Recognize when reliance on a Proposed Rule, Final Rule and/or Drug Monograph is appropriate
- Understand how to determine whether an Ingredient is considered Safe or GRAS/E for use in an OTC drug and understand the difference between Category I, II and II Ingredient designations
- Identify the required elements of a compliant OTC Drug Label
- Take away strategies for marketing and promoting OTC drug products, and for mitigating potential enforcement risks
- Possess a working knowledge of the Rx-to-OTC Switch Process
- Review and evaluate several of FDA's current OTC Monographs
- Regulatory affairs managers, directors and associates
- Compliance specialists
- Marketing managers
- Quality professionals
- Document control specialists
- Record retention specialists
- Senior Managers / Business Owners
- Product Managers
- Labeling and Artwork Designers
- Regulatory and Quality Professionals
- Sales and Marketing Managers
- R&D Managers and Staff
Speaker Profile
Dr. Loren Gelber has worked in the pharmaceutical industry for more than 40 years, at both the FDA and in private industry. She has prepared more than 50 submissions to the FDA. Her specialty is compliance with US regulatory requirements. She has a BA in Biology, an MS in Chemistry and a Ph.D. in Medicinal Chemistry.
Upcoming Webinars
California Meal and Rest Breaks: What You Dont Know Can Cos…
Responding to EEOC Discrimination Charges-What's Your Busin…
Implementing an Effective Human Error Reduction Program
Conflict Resolution - Prevent, De-escalate, Resolve
When Employees Travel: Wage and Expense Rules Employers Mus…
With Mandatory Paid Leave Gaining Ground Is It Time To Do A…
Female to Female Hostility @Workplace: All you Need to Know
Form 1099-MISC and 1099-NEC Compliance Update 2024
Validation Statistics for Non-Statisticians
The Totally Organized Professional Is All About Outcomes
Why EBITDA Doesn't Spell Cash Flow and What Does
GAMP5, Second Edition and Alignment with Computer Software …
Project Management for Non-Project Managers - Scheduling yo…
Sunshine Act Reporting - Clarification for Clinical Research
Understanding the Math of HR… So You Can Show How HR Impact…
FFIEC BSA/AML Examination Manual: What Compliance Officers …
How to Address ISO's New Climate Change Requirements
I-9 Audits: Strengthening Your Immigration Compliance Strat…
Re-imagine Finance & Accounting Made Simple. Three Webinars…
Stay Interviews: A Powerful and Low-Cost Employee Engagemen…
How To Conduct An Internal Harassment And Bullying Investig…
Effective Onboarding: How to Welcome, Engage, and Retain Ne…
Managing Toxic & Other Employees Who Have Attitude Issues
Analytical Method Validation Under Good Laboratory Practic…
Do's and Don'ts of Documenting Employee Behaviour, Performa…
Do's and Don'ts of Giving Effective Feedback for Performanc…
Onboarding New Hires: Leverage the Potential of Artificial …
Project Management for HR, Administrative Professionals, an…
Tattoos, hijabs, piercings, and pink hair: The challenges …
Using Behavior Based Interviewing for Finding the Best Matc…
How to Document Employee Discussions and Why it is Important
Stressed Out: How to Handle Conflict, Difficult People and …
Harassment, Bullying, Gossip, Confrontational and Disruptiv…
Best Practices for Working With Vendors and Suppliers
Understanding the Artificial Intelligence Landscape
Marketing to Medicare or Medicaid Beneficiaries - What You …
Accounting For Non Accountants : Debit, Credits And Financi…
Principles & Practices for the Cybersecurity of Legacy Medi…
Independent Contractor vs. Employee New Rule Issued by The …
Ultimate Persuasion Strategies! - Secret Influence Tools & …
Kicking your Employee Retention Efforts into Overdrive: Sta…